Exciting Developments in Encala® by Solace Nutrition
Solace Nutrition, a pioneering company in clinical nutrition, proudly presents fresh updates related to Encala®, a specialized plant-based structured-lipid medical food. Encala is engineered to cater to individuals facing fat malabsorption issues, deficiencies in fatty acids and choline, poor growth among children, and unintentional weight loss in adults.
Since the relaunch of Encala, the company has witnessed significant sales growth, surpassing initial expectations in both adult and pediatric nutritional care. Health care providers, familiar with Encala from its previous availability, have reported its effective benefits in promoting weight gain and alleviating gastrointestinal symptoms for patients dealing with malabsorption challenges.
"This past year has been transformative for us. We’ve established in-house manufacturing, comprehensively enhanced patient support services, and secured insurance coverage assistance through a dedicated team of health care professionals," stated Thomas Clough, CEO of Solace Nutrition. "Our foundation allows us to better serve the increasing demand from patients needing support for a variety of malabsorption conditions."
Addressing Diverse Malabsorption Needs
Encala is making a difference for patients suffering from pancreatic and intestinal diseases, short bowel syndrome, and various complex gastrointestinal conditions. Solace Nutrition aims to extend the reach of Encala globally, with a proposed launch in Canada within the next year and plans to enter markets in South America shortly after. The focus will be on patients with conditions like cystic fibrosis, rare pancreatic diseases, and those requiring nutritional support in intensive care units.
Groundbreaking Research Underpins Encala
The scientific development of Encala is anchored in outstanding results from a significant National Institutes of Health (NIH)-funded randomized clinical trial that involved over 100 children and adolescents with cystic fibrosis. With the leadership of renowned pediatric nutrition scientist Virginia Stallings, the trial showcased notable improvements in growth metrics and overall nutritional health.
This research effort also involved key contributors such as David Yesair, PhD, creator of the structured lipid compound, and lipid biochemist Walter Shaw, PhD, who was instrumental in developing the original formulation. From this endeavor, the team has published numerous peer-reviewed papers, highlighting their findings at both national and international forums.
Thanks to generous funding and backing from established organizations, over $17 million has been funneled into ensuring Encala's continuing advancement. A pivotal achievement in this journey was the establishment of a CMS reimbursement code, which significantly enhances accessibility and insurance coverage for those qualifying.
Innovative Studies and Research Initiatives
The pursuit of research involving Encala is extensive. A recently initiated study, backed by the Department of Defense, investigates the nutritional effects of Encala on individuals with pancreatic cancers, aiming to enhance their gastrointestinal comfort and overall quality of life during treatment.
Exploring New Horizons: Cerebral Palsy
A new study exploring Encala's impact on children and adults with moderate to severe cerebral palsy who require enteral feeding is poised to start enrollment soon.
Advancements in Oral Drug Delivery
Encala's structured-lipid technology is generating interest in the pharmaceutical space, demonstrating improved absorption for lipid-soluble medications in trials, with promising results in ongoing studies.
Nutrition Data System's Inclusion of Encala
Encala has found its place within the Nutrition Data System for Research (NDSR®), a highly regarded dietary analysis tool widely used in clinical and epidemiological research across North America. This inclusion facilitates a thorough assessment of Encala intake in current research projects.
Veterinary Nutrition Insights
Encala's impact isn't limited to human health. Recent studies show encouraging results in malnourished dogs, proving its safety and effectiveness, as demonstrated by weight gain and healthy body mass outcomes.
About Structured Lipid Nutrition
Structured Lipid Nutrition was founded to address unmet medical needs through evidence-based nutritional advancements encompassing both human and veterinary medicine. By preserving the integrity of the Encala brand, SLN collaborates with Solace Nutrition to ensure exemplary manufacturing and distribution practices.
About Solace Nutrition
At the forefront of medical nutrition, Solace Nutrition specializes in developing innovative medical foods that cater to individuals facing intricate metabolic and chronic conditions. With two decades of experience, the company is committed to enhancing patient outcomes through access to specialized nutrition that supports improved health and well-being.
Frequently Asked Questions
What is Encala® and what purpose does it serve?
Encala® is a structured-lipid medical food designed to help individuals with fat malabsorption and related nutritional deficiencies.
How has the market response been after Encala's relaunch?
Sales for Encala have exceeded expectations, and many healthcare providers have recognized its benefits for both adult and pediatric patients.
What kind of research supports the effectiveness of Encala?
Encala's efficacy is backed by extensive clinical trials, including major studies funded by the NIH demonstrating improvements in patient growth and nutritional status.
Are there expansion plans for Encala®?
Yes, Solace Nutrition plans to expand Encala’s availability internationally, with launches anticipated in Canada and South America.
Who can benefit from Encala®?
Patients with conditions such as cystic fibrosis, short bowel syndrome, and other gastrointestinal diseases can benefit from Encala®.
